Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism
© The Author(s), under exclusive licence to Association of Clinical Biochemists of India 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law..
In this study, it was aimed to assess effects of subclinical hyperthyroidism (SH) on bone metabolism using osteoprotegerin (OPG), sclerostin, Dickkopf-1 (DKK1) and biochemical parameters. This cross-sectional prospective study included 40 patients with SH and 40 euthyroid controls. Serum OPG, sclerostin, DKK-1, type-1 procollagen, C-terminal polypeptide (CTx) and 24-hours urine N-terminal telopeptide (NTx) were measures using ELISA kit. Bone mineral density measurements were performed using dual energy X-ray absorptiometry (DEXA). Risk for 10-years hip and major fracture was estimated by Turkish version of FRAX. No significant difference was detected in age, gender, body mass index, smoking and menopause rates between SH and control groups. The risk for 10-years hip fracture and major osteoporotic fracture were estimated as 4.45% and 0.55% in SH group, respectively. The OPG levels were significantly lower in patients with SH than controls (P = 0.017). No significant difference was detected in other bone formation and degradation parameters. No significant correlation was detected between OPG level and risk for major osteoporotic fracture (P > 0.05); however, a negative correlation was detected between OPG level and risk for hip fracture (rho = 0.233; P = 0.038). Serum OPG is markedly affected in patients with SH. In addition, OPG seemed to be associated with osteoporotic fracture risk. Available data show that SH is significantly associated with risk for fracture; thus, it is important to assess risk for fracture in patients with SH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Indian journal of clinical biochemistry : IJCB - 39(2024), 1 vom: 12. Jan., Seite 130-135 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Özbek, Ayşe Elverdi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bone metabolism |
|---|
| Anmerkungen: |
Date Revised 16.01.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s12291-022-01080-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367135515 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367135515 | ||
| 003 | DE-627 | ||
| 005 | 20240116232100.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12291-022-01080-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM367135515 | ||
| 035 | |a (NLM)38223003 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Özbek, Ayşe Elverdi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), under exclusive licence to Association of Clinical Biochemists of India 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a In this study, it was aimed to assess effects of subclinical hyperthyroidism (SH) on bone metabolism using osteoprotegerin (OPG), sclerostin, Dickkopf-1 (DKK1) and biochemical parameters. This cross-sectional prospective study included 40 patients with SH and 40 euthyroid controls. Serum OPG, sclerostin, DKK-1, type-1 procollagen, C-terminal polypeptide (CTx) and 24-hours urine N-terminal telopeptide (NTx) were measures using ELISA kit. Bone mineral density measurements were performed using dual energy X-ray absorptiometry (DEXA). Risk for 10-years hip and major fracture was estimated by Turkish version of FRAX. No significant difference was detected in age, gender, body mass index, smoking and menopause rates between SH and control groups. The risk for 10-years hip fracture and major osteoporotic fracture were estimated as 4.45% and 0.55% in SH group, respectively. The OPG levels were significantly lower in patients with SH than controls (P = 0.017). No significant difference was detected in other bone formation and degradation parameters. No significant correlation was detected between OPG level and risk for major osteoporotic fracture (P > 0.05); however, a negative correlation was detected between OPG level and risk for hip fracture (rho = 0.233; P = 0.038). Serum OPG is markedly affected in patients with SH. In addition, OPG seemed to be associated with osteoporotic fracture risk. Available data show that SH is significantly associated with risk for fracture; thus, it is important to assess risk for fracture in patients with SH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bone metabolism | |
| 650 | 4 | |a DKK-1 | |
| 650 | 4 | |a Osteoprotegerin | |
| 650 | 4 | |a Sclerostin | |
| 650 | 4 | |a Subclinical hyperthyroidism | |
| 700 | 1 | |a Korkmaz, Hüseyin |e verfasserin |4 aut | |
| 700 | 1 | |a Sözen, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a İpekçi, Süleyman Hilmi |e verfasserin |4 aut | |
| 700 | 1 | |a Abuşoğlu, Sedat |e verfasserin |4 aut | |
| 700 | 1 | |a Kıraç, Cem Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Ünlü, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Kebapçılar, Levent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian journal of clinical biochemistry : IJCB |d 1996 |g 39(2024), 1 vom: 12. Jan., Seite 130-135 |w (DE-627)NLM086804820 |x 0970-1915 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2024 |g number:1 |g day:12 |g month:01 |g pages:130-135 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12291-022-01080-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2024 |e 1 |b 12 |c 01 |h 130-135 | ||